Verastem, Inc. (LON:0LOV)

Market Cap	358.64M +66.9%
Revenue (ttm)	9.95M +33.8%
Net Income	-179.37M
EPS	-2.96
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,308
Average Volume	1,988
Open	6.46
Previous Close	6.20
Day's Range	5.97 - 6.46
52-Week Range	4.08 - 11.17
Beta	0.44
RSI	36.36
Earnings Date	Mar 17, 2026

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2010
• Employees: 78
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0LOV

Financial Performance

Financial numbers in USD